Bodal Chemicals Presents Investor Presentation for November 2026
Bodal Chemicals reports record H1FY27 revenue of ₹15,991 million (67% YoY growth) and EBITDA of ₹2,027 million (114% YoY growth). Q2FY27 revenue was ₹8,840 million (77% YoY growth) with EBITDA at ₹1,276 million (197% YoY growth). Net profit for Q2FY27 surged by 1259% YoY to ₹814 million.
The announcement details significant financial performance improvements and highlights a positive outlook, which is material information for investors.
The company has reported record revenues and significant year-on-year growth in revenue, EBITDA, and net profit, indicating strong financial performance.
Bodal Chemicals Limited has submitted an Investor Presentation for November 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The presentation highlights significant financial performance for H1FY27, with total revenue reaching an all-time high of ₹15,991 million, marking a 67% year-on-year growth. This growth is attributed to better realization and improved volumes across divisions. The company achieved its highest absolute EBITDA of ₹2,027 million, a 114% YoY increase for the first half of the year. In Q2FY27, total revenue stood at ₹8,840 million (77% YoY growth), with EBITDA at ₹1,276 million (197% YoY growth) and a 14.4% margin. Net profit for Q2FY27 was ₹814 million, showing a substantial 1259% YoY growth.
Revenue from Dye intermediates grew by 68% in H1FY27, Dyestuff by 42%, and Basic Chemicals by 136% YoY, primarily due to increased prices of raw materials like Sulphur. In Q2FY27, Dye Intermediates revenue grew by 88% YoY, Basic Chemicals by 199% YoY, and Dyestuffs by 60% YoY.
The Chlor Alkali business saw a 6% YoY revenue growth in H1FY27 and an 8% quarterly YoY growth in Q2FY27. The Benzene downstream products division in Saykha has started contributing to the topline. The company's subsidiaries in Turkey, China, and BCTPL also performed satisfactorily in Q2FY27.
Bodal Chemicals anticipates continued strong performance in coming quarters due to structural changes in China and stabilization of the Benzene downstream products plant. The company emphasizes its integrated business model, strong R&D, and experienced management team as key strengths. The presentation also details its diversified product portfolio, manufacturing facilities, and commitment to environmental compliance and sustainability.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.